




RealRate

PHARMACEUTICAL 2021

CHINOOK THERAPEUTICS INC.
Rank 105 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

CHINOOK THERAPEUTICS INC. Rank 105 of 409



The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 52% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Revenues, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 369% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 254,081 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 50,137 |
| Liabilities, Current | 22,809 |
| Liabilities, Non-Current | 39,614 |
| Other Assets | 124,784 |
| Other Compr. Net Income | 18 |
| Other Expenses | 27,640 |
| Other Liabilities | 31,957 |
| Other Net Income | 313 |
| Property and Equipment | 0 |
| Research and Development | 36,051 |
| Revenues | 827 |
| Selling, General and Administrative Expense | 19,071 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 429,002 |
| Liabilities | 94,380 |
| Expenses | 82,762 |
| Stockholders Equity | 334,622 |
| Net Income | -81,622 |
| Comprehensive Net Income | -81,613 |
| Economic Capital Ratio | 14% |

